Results 11 to 20 of about 265 (112)

RNA Interference Therapeutics in Cardiology: Focus on Zilebesiran and Olpasiran [PDF]

Journal of Education, Health and Sport
Background: RNA interference (RNAi) therapeutics represent a novel approach in cardiovascular medicine, enabling durable and selective inhibition of disease-relevant proteins.
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Jarosław Pietrzak   +3 more
doaj   +3 more sources

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial.

JAMA
ImportanceAngiotensinogen is the most upstream precursor of the renin–angiotensin–aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an investigational RNA interference therapeutic, targets hepatic angiotensinogen synthesis.ObjectiveTo evaluate antihypertensive efficacy and safety of different zilebesiran dosing regimens ...
Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, Makarova N, Goyal N, Guo W, Zappe D, Desai AS, KARDIA-1 Study Group.   +11 more
europepmc   +4 more sources

Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?

Expert Opinion on Biological Therapy
Less than half of the subjects with hypertension have been diagnosed and treated, with only 21% having their blood pressure under control. Many of the subjects find it difficult to adhere to daily antihypertensives. Zilebesiran reduces hepatic angiotensinogen messenger RNA levels to inhibit the renin-angiotensin-aldosterone system and is being ...
Doggrell, Sheila A
exaly   +5 more sources

New Pharmacologic Approaches in Hypertension: Baxdrostat and Zilebesiran with Insights from BaxHTN and KARDIA-3 Trials [PDF]

Journal of Education, Health and Sport
Background: Resistant and uncontrolled hypertension remains a major cardiovascular risk factor worldwide. Emerging therapies targeting the renin-angiotensin-aldosterone system (RAAS), including Baxdrostat and Zilebesiran, offer potential benefits ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowsla, Jarosław Pietrzak   +3 more
doaj   +2 more sources

A Pairwise and Network Meta-Analysis Comparing the Efficacy and Safety of Ribonucleic Acid Interference Therapeutics in the Management of Hypertension [PDF]

ASIDE Internal Medicine
Background: Small interfering RNA (siRNA) and antisense agents targeting angiotensinogen are emerging antihypertensives. We synthesized their efficacy and safety.
Mohamed E. Haseeb, Zeyad Bady, Hazem E. Mohammed, George Hanen, Mohamed Nasser, Nada S. Jibril, Mohamed Khalafalla Darwish, Heba Aboeldahab   +7 more
doaj   +2 more sources

Efficacy and Safety of Zilebesiran for the Management of Hypertension: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials. [PDF]

Cureus
Zilebesiran is a novel RNA interference (RNAi) therapeutic agent that reduces the production of hepatic angiotensinogen, showing promising results in the management of hypertension. However, a comprehensive assessment of its efficacy and safety is still required.
Raza M, Riaz CZ, Chaudhry ER, Jannat M, Basit AR, Qureshi AJ, Qureshi MH, Ahmed MW.   +7 more
europepmc   +3 more sources

RNA interference therapy in cardiology: will new targets improve therapeutic goals? [PDF]

Drugs in Context
The discovery of RNA interference in 1998 opened avenues for the manipulation of gene expression, leading to the development of small interfering RNA (siRNA) drugs.
Renata TJ Fazoli, Luciano F Drager, Roberto Kalil-Filho, Giuliano Generoso   +3 more
doaj   +2 more sources

Zilebesiran — the first siRNA-based drug in hypertensiology: why is it needed, and will it change the treatment approach of hypertension?

Arterial Hypertension
Arterial hypertension is the most common cardiovascular risk factor in the world. The prevalence of hypertension has doubled over the last 30 years.
Stanisław Surma, Suzanne Oparil
doaj   +3 more sources

Safety and Efficacy of Novel RNA Interference Therapeutic Agent Zilebesiran in People With Hypertension: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Hypertension is a major risk factor for cardiovascular and renal diseases. Despite the availability of a wide variety of anti-hypertensive agents, a large number of patients on anti-hypertensive therapy have uncontrolled hypertension. Several factors, such as incorrect dosage and treatment non-adherence due to side effects, polypharmacy, and complex ...
Singh V, Tewari J, Qidwai KA, Singh SK, Tewari A, Tewari V, Maheshwari A.   +6 more
europepmc   +3 more sources

Hypertension Cure Research progress: The use of Zilebesiran in Hypertension

Endocrinology and Disorders
Chronic hypertension is a lifelong condition, and the patients need lifelong treatment with oral anti-hypertensive medications to say healthy and to prevent the development of serious complications. Demands for changing this situation of lifelong dependence on daily medications have been increasing.
exaly   +2 more sources